stockrowFemasys Inc.
FEMY Healthcare Medical Instruments & Supplies
Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024.
- Revenue
- −18.9%
- EPS
- +58.4%
- Free cash flow
- +11.3%
- Total debt
- +3,369.3%
Quarter to June 2026, against a year earlier
Follow FEMY
Alert me
Femasys Inc. (FEMY) EV/Sales
As of 5 November 2026, Femasys Inc. (FEMY) trades at a EV/Sales of 2.9×. Over the past ten years it has ranged from −12.9× (September 2021) to 60.8× (June 2021); the current reading is higher than 35% of that period. That is in line with the Medical Instruments & Supplies industry median of 2.8× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 14.1× | 8.73% |
| FY2024 | 13.0× | 220.89% |
| FY2023 | 4.0× | — |
| FY2022 | −1.8× | — |
| FY2021 | 1.3× | (97.82%) |
| FY2020 | 60.8× | 0.00% |
| FY2020 | 60.8× | 0.00% |
| FY2019 | 60.8× | 0.00% |
| FY2019 | 60.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.0× | (36.86%) |
| Mar 2026 | 11.2× | (21.00%) |
| Dec 2025 | 14.1× | 191.50% |
| Sep 2025 | 4.8× | (63.09%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RVP Retractable Technologies, Inc. compare | −0.7× |
| RGNT Regentis Biomaterials Ltd. compare | n/m |
| CUPR Cuprina Holdings (Cayman) Limited compare | n/m |
| MHUAF Meihua International Medical Technologies Co., Ltd. compare | n/m |
| NXGL NexGel, Inc. compare | 0.3× |
| LUCY Innovative Eyewear, Inc. compare | 0.5× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| MLSS Milestone Scientific, Inc. compare | 2.8× |
| FEMY Femasys Inc. | 2.9× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)